In Teva Branded Pharma. Prods R&D, Inc. v. Amneal Pharma. of NY, LLC, the US Court of Appeals for the Federal Circuit affirmed the district court’s order requiring a branded pharmaceutical company to delist patents from the Orange Book because those patents claimed components of the drug delivery system rather than the drug’s active ingredient.
Source link
Orange Book Listed Patents Must Claim Approved Drug's Active Ingredient: Federal Circuit
